Drugs / Bedrocan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05235503 | Dec 2021 → Dec 2022 | respiratory underresponsiveness to hypoxia and hypercapnia, substance-related disorder | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05939466 | Mar → Sep 2021 | fibromyalgia | University of Basilicata | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bedrocan | “At t = 1.5 h and at t = 4.5 h the subject will inhale 100 mg Bedrocan.” NCT05235503 ↗ |
| Known as | Medicinal Cannabis | “The goal of this interventional study is to learn about the effect of Medicinal Cannabis (Bedrocan®) on Fibromyalgia patients with pain resistant to conventional therapy.” NCT05939466 ↗ |
| Route | Inhaled | “At t = 1.5 h and at t = 4.5 h the subject will inhale 100 mg Bedrocan.” NCT05235503 ↗ |